Official Journal of the European Union

C 380/10

Prior notification of a concentration

(Case M.7833 — CDC International Capital/Mubadala Development Company/Vivalto Bel/Groupe Vivalto Santé)

(Text with EEA relevance)

(2015/C 380/09)


On 9 November 2015 the European Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which Vivalto Bel (Belgium), CDC International Capital (France) and Mubadala Development Company PJSC (‘Mubadala’, Abu Dhabi) acquire within the meaning of Article 3(1)(b) of the Merger Regulation joint control of Groupe Vivalto Santé (France) by way of purchase of shares.


The business activities of the undertakings concerned are:

—   Vivalto Bel: family holding company investing mainly in the health sector,

—   CDC International Capital: subsidiary of the Caisse des Dépôts et Consignations specialising in direct investments in partnership with sovereign wealth funds and international institutional investors,

—   Mubadala: sovereign wealth fund of Abu Dhabi in the United Arab Emirates,

—   Groupe Vivalto Santé: operator of private health establishments in France.


On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved.


The Commission invites interested third parties to submit to it their observations on the proposed operation.

Observations must reach the Commission no later than 10 days following the date on which this notification is published. They can be sent to the Commission under reference M.7833 — CDC International Capital/Mubadala Development Company/Vivalto Bel/Groupe Vivalto Santé, by fax (+32 22964301), by e-mail to COMP-MERGER-REGISTRY@ec.europa.eu or by post to the following address:

European Commission

Directorate-General for Competition

Merger Registry

1049 Bruxelles/Brussel


(1)  OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).